FDA clears Turnstone Biologics’ IND for immunotherapy targeting HPV positive solid tumors – News-Medical.net
News-Medical.net |
FDA clears Turnstone Biologics' IND for immunotherapy targeting HPV positive solid tumors
News-Medical.net Turnstone's MG1 virus is the first immunotherapy engineered to function as both a selective tumor-destroying oncolytic virus and an immune stimulating T cell vaccine. MG1 directly attacks cancer cells and modifies the microenvironment to make tumor … |
